Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The application for Tecentriq as a first-line monotherapy for NSCLC patients without EGFR or ALK mutations and high PD-L1 expression was also granted priority review.
Following the accelerated approval for tazemetostat last month, the new supplement application could poise it as the first EZH2 inhibitor for follicular lymphoma.
